Xilio Therapeutics, Inc.

NasdaqGS:XLO Stock Report

Market Cap: US$42.7m

Xilio Therapeutics Management

Management criteria checks 1/4

Xilio Therapeutics' CEO is Rene Russo, appointed in May 2019, has a tenure of 5.58 years. total yearly compensation is $3.00M, comprised of 19.9% salary and 80.1% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth $195.06K. The average tenure of the management team and the board of directors is 1.3 years and 3.9 years respectively.

Key information

Rene Russo

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage19.9%
CEO tenure5.6yrs
CEO ownership0.5%
Management average tenure1.3yrs
Board average tenure3.9yrs

Recent management updates

Recent updates

Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth

Oct 25
Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth

Here's Why We're A Bit Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation

Jul 12
Here's Why We're A Bit Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation

We Think Xilio Therapeutics (NASDAQ:XLO) Needs To Drive Business Growth Carefully

Aug 11
We Think Xilio Therapeutics (NASDAQ:XLO) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Rene Russo's remuneration changed compared to Xilio Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$63m

Jun 30 2024n/an/a

-US$66m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$3mUS$598k

-US$76m

Sep 30 2023n/an/a

-US$81m

Jun 30 2023n/an/a

-US$84m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$2mUS$575k

-US$88m

Sep 30 2022n/an/a

-US$85m

Jun 30 2022n/an/a

-US$82m

Mar 31 2022n/an/a

-US$80m

Dec 31 2021US$5mUS$485k

-US$76m

Sep 30 2021n/an/a

-US$77m

Jun 30 2021n/an/a

-US$75m

Mar 31 2021n/an/a

-US$64m

Dec 31 2020US$3mUS$450k

-US$55m

Compensation vs Market: Rene's total compensation ($USD3.00M) is above average for companies of similar size in the US market ($USD646.54K).

Compensation vs Earnings: Rene's compensation has increased whilst the company is unprofitable.

CEO

Rene Russo (49 yo)

5.6yrs

Tenure

US$2,999,910

Compensation

Dr. Rene Russo, BCPS, PharmD., serves as Director at Celsius Therapeutics, Inc. since May 2020. Since May 2019, Dr. Russo has been the Chief Executive Officer and Director of Xilio Therapeutics, Inc., (for...

Leadership Team

NamePositionTenureCompensationOwnership
Rene Russo
President5.6yrsUS$3.00m0.46%
$ 195.1k
Christopher Frankenfield
Chief Operating Officer1.3yrsUS$1.86m0%
$ 0
Katarina Luptakova
Chief Medical Officer1.3yrsUS$932.17k0%
$ 0
Kevin Brennan
Senior VP of Finance & Accounting1.7yrsno datano data
Uli Bialucha
Chief Scientific Officer2.3yrsno datano data
Caroline Hensley
Chief Legal Officerno datano datano data
Scott Coleman
Chief Development Officer1.3yrsno datano data

1.3yrs

Average Tenure

48.5yo

Average Age

Experienced Management: XLO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Rene Russo
President5.6yrsUS$3.00m0.46%
$ 195.1k
Paul Clancy
Non-Employee Independent Chairman4.4yrsUS$96.77k0%
$ 0
Daniel Curran
Independent Director4yrsno datano data
Sara Bonstein
Independent Director3.3yrsUS$76.77k0%
$ 0
Christina Rossi
Independent Director3.7yrsUS$78.05k0%
$ 0
Jason J. Luke
Member of Scientific Advisory Board3.9yrsno datano data
Deborah Charych
Member of Scientific Advisory Boardno datano datano data
Christopher Hunter
Member of Scientific Advisory Boardno datano datano data
Anthony O'Donoghue
Member of Scientific Advisory Boardno datano datano data
Jamie Spangler
Member of Scientific Advisory Board3.9yrsno datano data
Kwok-Kin Wong
Member of Scientific Advisory Board3.9yrsno datano data
Andy Minn
Member of Scientific Advisory Board3.9yrsno datano data

3.9yrs

Average Tenure

53yo

Average Age

Experienced Board: XLO's board of directors are considered experienced (3.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 03:23
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xilio Therapeutics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Michael KingH.C. Wainwright & Co.
Michael UlzMorgan Stanley